Philips Healthcare has reported a single-digit increase in sales for the fourth quarter of 2011 over the comparable 2010 fourth quarter, and the 2011 fiscal year over 2010.

Venture investments held strong and steady across healthcare in 2011, with medical devices finishing a close second to biopharmaceuticals in dollars invested and healthcare IT seeing a substantial increase over the previous year.

GE Healthcare has reported a 1 percent increase in fourth quarter revenues to $5.16 billion, and a slight drop—5 percent—in quarter profits to $953 million. However, the yearly revenue in 2011 rose 7 percent in 2011 over 2010—$18.08 billion versus $16.9 billion. Likewise, the healthcare unit’s yearly profits rose 2 percent from $2.74 billion in 2010 to $2.8 billion in 2011.

Nordion has reported increases in net income and revenue for the fiscal year (FY) 2011, despite losses in the fourth quarter. Also, the company made its predictions for how its isotopes unit will perform in FY2012.

The Medical Imaging & Technology Alliance (MITA) was awarded money from the Commerce Department’s International Trade Administration Market Development Cooperator program to increase exports and expand access to diagnostic medical imaging, radiation therapy and radiopharmaceuticals in new markets.

Royal Philips Electronics has released its earnings report for the first quarter of 2011. Overall, Philips’ group sales were EUR 5.3 ($7.5 USD) billion, with EBITA of EUR 437 ($622 USD) million, or 8 percent of sales.

Novelos Therapeutics has completed its acquisition of Cellectar and $5.1 million financing to develop three novel cancer-targeted compounds.

Royalty Pharma has acquired the rights to certain royalties payable on sales of the pharmacologic stress agent Lexiscan and the antibiotic Cubicin from an undisclosed seller for a cash payment of $487 million.

InSight Imaging and its subsidiaries have emerged from Chapter 11 bankruptcy, marking the elimination of nearly $300 million worth of debt and prepackaged corporate restructuring.

IsoRay, which manufactures Cesium-131 used in internal radiation therapy (brachytherapy) for the treatment of lung, brain, colon, head and neck, ocular melanoma and prostate cancer, has announced its second quarter financial results that showed narrowing of net losses despite a decrease in net sales, which ended Dec. 31, 2010.